medigraphic.com

2024, Number 2

<< Back Next >>

rev homeostasis 2024; 6 (2)

Manifestaciones oftalmológicas en las enfermedades autoinmunes del tejido conectivo: Una revisión de la literatura

Marmolejo-Bedolla LI, Acevedo-Rodríguez JE, Jeong SH

Language: Spanish
References: 37
Page:
PDF size: 177.87 Kb.


ABSTRACT

Connective tissue autoimmune pathologies can have systemic manifestations, but focusing on ophthalmological manifestations, these can range from relatively mild and easily treatable to those that threaten vision. In rheumatoid arthritis and systemic lupus erythematosus, the most common is dry eye due to decreased tear production, but manifestations in other parts of the eye are also common. In Sjögren's syndrome, the distinctive sign and primary glandular manifestation is Sicca syndrome; however, this pathology can affect multiple systems and have different levels of systemic involvement. In systemic sclerosis, obliterative vasculopathy is the most important characteristic; however, there are other ophthalmological manifestations. Although the diagnosis and management of these pathologies require coordination between emergency physicians, rheumatologists, and ophthalmologists, it is the latter who, at times, can be the first line of detection of autoimmune pathologies due to the frequency of ophthalmological manifestations as a reason for consultation. In the ophthalmological context, the treatment of these manifestations focuses on relieving symptoms and preventing complications.


REFERENCES

  1. Murray PI, Rauz S. The eye and inflammatoryrheumatic diseases: The eye and rheumatoidarthritis, ankylosing spondylitis, psoriaticarthritis. Best Pract Res Clin Rheumatol. 2016Oct;30(5):802-825.

  2. Steiner M, Esteban-Ortega M, Muńóz-FernándezS. Choroidal and retinal thickness in systemicautoimmune and inflammatory diseases: Areview. Survey of Ophthalmology 64 (2019);757-769.

  3. Roszkowska AM, Oliverio GW, Aragona E,Inferrera L, Severo AA, Alessandrello F, SpinellaR, Postorino EI, Aragona P. OphthalmologicManifestations of Primary Sjögren's Syndrome.Genes (Basel). 2021 Mar 4;12(3):365.

  4. Aletaha D, Smolen JS. Diagnosis andManagement of Rheumatoid Arthritis: A Review.JAMA .2018;320(13):1360–1372.

  5. Frazzei G, Musters A, de Vries N, Tas SW, vanVollenhoven RF. Prevention of rheumatoidarthritis: A systematic literature review ofpreventive strategies in at-risk individuals.Autoimmun Rev. 2023 Jan;22(1):103217.

  6. Miguel-Lavariega D, Elizararrás-Rivas J,Villarreal-Ríos E, Baltiérrez-Hoyos R,Velasco-Tobón U, Vargas-Daza ER,Galicia-Rodríguez L. Perfil epidemiológico de laartritis reumatoide [Epidemiological profile ofrheumatoid arthritis]. Rev Med Inst Mex SeguroSoc. 2023 Sep 4;61(5):574-582.

  7. Mendoza-Vázquez G, Rocha-Muńoz AD,Guerra-Soto AJ, et al. Artritis reumatoide ydislipidemias. Residente. 2013;8(1):12-22.

  8. Jang S, Kwon EJ, Lee JJ. Rheumatoid Arthritis:Pathogenic Roles of Diverse Immune Cells. Int JMol Sci. 2022 Jan 14;23(2):905.

  9. Conigliaro P, Triggianese P, De Martino E, FontiGL, Chimenti MS, Sunzini F, Viola A, Canofari C,Perricone R. Challenges in the treatment ofRheumatoid Arthritis. Autoimmun Rev. 2019Jul;18(7):706-713.

  10. Sparks JA. Rheumatoid Arthritis. Ann InternMed. 2019 Jan 1;170(1):ITC1-ITC16.

  11. Figus FA, Piga M, Azzolin I, McConnell R,Iagnocco A. Rheumatoid arthritis: Extra-articularmanifestations and comorbidities. AutoimmunRev. 2021 Apr;20(4):102776.

  12. Kłodziński Ł, Wisłowska M. Comorbidities inrheumatic arthritis. Rheumatology.2018;56(4):228-33.

  13. Thompson L, Patrianakos T, Garcia T, et al.Autoimmune Disorders and the Eye.Disease-aMonth. April 2024;2:47.https://doi.org/10.1016/j.disamonth.2024.101711

  14. Zlatanović G, Veselinović D, Cekić S, Živković M,Đorđević-Jocić J, Zlatanović M. Ocularmanifestation of rheumatoid arthritis-differentforms and frequency. Bosnian Journal of basicmedical sciences. 2010; 10 (4): 323-327

  15. González Jiménez D, Mejía Bonilla S, Cruz FallasM. Lupus eritematoso sistémico: enfoquegeneral de la enfermedad. Rev méd sinerg.2021;6(1):e630. Disponible en:https://revistamedicasinergia.com/index.php/rms/article/view/630.

  16. Narváez J. Lupus eritematoso sistémico 2020.Med Clin (Barc). 2020;155(11):494-501.doi:10.1016/j.medcli.2020.05.009.

  17. Stojan G, Petri M. Epidemiology of systemiclupus erythematosus: an update. Curr OpinRheumatol. 2018 Mar;30(2):144-150. doi:10.1097/BOR.0000000000000480. PMID:29251660; PMCID: PMC6026543.

  18. Dörner T, Furie R. Novel paradigms in systemiclupus erythematosus. Lancet. 2019 Jun8;393(10188):2344-2358. doi:10.1016/S0140-6736(19)30546-X. Epub 2019Jun 6. PMID: 31180031.

  19. Fava A, Petri M. Systemic lupus erythematosus:Diagnosis and clinical management. JAutoimmun. 2019 Jan;96:1-13. doi:10.1016/j.jaut.2018.11.001. Epub 2018 Nov 16.PMID: 30448290; PMCID: PMC6310637.

  20. Durcan L, O'Dwyer T, Petri M. Managementstrategies and future directions for systemiclupus erythematosus in adults. Lancet. 2019 Jun8;393(10188):2332-2343. doi:10.1016/S0140-6736(19)30237-5. Epub 2019Jun 6. PMID: 31180030.

  21. Fanouriakis A, Tziolos N, Bertsias G, BoumpasDT. Update οn the diagnosis and managementof systemic lupus erythematosus. Ann RheumDis. 2021 Jan;80(1):14-25. doi:10.1136/annrheumdis-2020-218272. Epub 2020Oct 13. PMID: 33051219.

  22. Aringer M, Costenbader K, Daikh D, Brinks R,Mosca M, Ramsey-Goldman R, et al. 2019European League Against Rheumatism/AmericanCollege of Rheumatology Classification Criteriafor Systemic Lupus Erythematosus. ArthritisRheumatol. 2019 Sep;71(9):1400-1412. doi:10.1002/art.40930.

  23. Shoughy SS, Tabbara KF. Review article: Ocularfindings in systemic lupus erythematosus. SaudiJournal of Ophthalmology. 2016Apr-Jun;30(2):117-21. doi:10.1016/j.sjopt.2016.02.001.

  24. Akpek EK, Bunya VY, Saldanha IJ. Sjögren'sSyndrome: More Than Just Dry Eye. Cornea.2019 May;38(5):658-661. doi:10.1097/ICO.0000000000001865. PMID:30681523; PMCID: PMC6482458.

  25. Negrini S, Emmi G, Greco M, Borro M, SardanelliF, Murdaca G, Indiveri F, Puppo F. Sjögren'ssyndrome: a systemic autoimmune disease. ClinExp Med. 2022 Feb;22(1):9-25. doi:10.1007/s10238-021-00728-6. Epub 2021 Jun 7.PMID: 34100160; PMCID: PMC8863725.

  26. Fasano S, Mauro D, Macaluso F, Xiao F, Zhao Y,Lu L, Guggino G, Ciccia F. Pathogenesis ofprimary Sjögren's syndrome beyond Blymphocytes. Clin Exp Rheumatol. 2020Jul-Aug;38 Suppl 126(4):315-323.

  27. Chatzis L, Vlachoyiannopoulos PG, Tzioufas AG,Goules AV. New frontiers in precision medicinefor Sjogren's syndrome. Expert Rev ClinImmunol. 2021 Feb;17(2):127-141. doi:10.1080/1744666X.2021.1879641. Epub 2021Feb 5. PMID: 33478279.

  28. Skarlis C, Raftopoulou S, Mavragani CP.Sjogren's Syndrome: Recent Updates. J ClinMed. 2022 Jan 13;11(2):399. doi:10.3390/jcm11020399. PMID: 35054094;PMCID: PMC8778847.

  29. Akpek EK, Bunya VY, Saldanha IJ. Sjögren’sSyndrome: More Than Just Dry Eye. Cornea.2019 May ; 38(5): 658–661.doi:10.1097/ICO.0000000000001865.

  30. Both T, Dalm V, Martin van Hagen P, Vam DaeleP. Reviewing primary Sjögren’s syndrome:beyond the dryness - From pathophysiology todiagnosis and treatment. International Journalof Medical Sciences, 2017; 14(3): 191-200. doi:10.7150/ijms.17718

  31. Baldini C, Pepe P, Quartuccio L, Priori R, et. al.Primary Sjogren’s syndrome as a multi-organdisease: impact of the serological profile on theclinical presentation of the disease in a largecohort of Italian patients. Rheumatology Oxford2014;53:839844.doi:10.1093/rheumatology/ket427

  32. Hughes M, Herrick AL. Systemic sclerosis. Br JHosp Med. 2019;80(9):530–536.

  33. Rosendahl AH, Schönborn K, Krieg T.Pathophysiology of systemic sclerosis(scleroderma). Kaohsiung J Med Sci. 2022Mar;38(3):187-195.

  34. Volkmann ER, Andréasson K, Smith V. Systemicsclerosis. Lancet. 2023 Jan28;401(10373):304-318.

  35. Denton CP, Khanna D. Systemic sclerosis.Lancet. 2017 Oct 7;390(10103):1685-1699.

  36. Zamorano M, Redondo I, González-López, M.Edema macular bilateral en esclerosis sistémica.Archivos de la Sociedad Espańola deOftalmología 2024; 02, 006

  37. Ingegnoli F, Gualtierotti R, Pierro L, et. al.Choroidal impairment and macular thinning inpatients with systemic sclerosis: the acute study.Microvasc Res 2015; 97: pp. 31-36.




2020     |     www.medigraphic.com